Compare · CTNM vs NVO
CTNM vs NVO
Side-by-side comparison of Contineum Therapeutics Inc. (CTNM) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTNM and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 584.3x CTNM ($297.2M).
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for CTNM).
- NVO has more recent analyst coverage (25 ratings vs 6 for CTNM).
- Company
- Contineum Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $7.07-10.51%
- $38.82-1.05%
- Market cap
- $297.2M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 1
- 4
- Recent ratings
- 6
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CTNM
- Contineum Therapeutics downgraded by Robert W. Baird with a new price target
- Contineum Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
- CEO and President Stengone Carmine N. exercised 2,500 shares at a strike of $1.01 and sold $41,142 worth of shares (2,500 units at $16.46) as part of a pre-agreed trading plan (SEC Form 4)
- Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.
- CEO and President Stengone Carmine N. sold $40,029 worth of shares (2,500 units at $16.01) as part of a pre-agreed trading plan and exercised 2,500 shares at a strike of $1.01 (SEC Form 4)
- SEC Form 10-Q filed by Contineum Therapeutics Inc.
- Contineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank